Plasma growth hormone (GH)-releasing hormone levels in patients with lung carcinoma

J. Schopohl, M. Losa, C. Frey, G. Wolfram, R. Huber, W. Permanetter, J. Von Pawel, O. A. Muller, K. Von Werder

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objective: The aim was to investigate the serum levels of growth hormone releasing hormone and GH in patients with lung carcinoma. Design: After an overnight fast a plasma sample was collected for determination of growth hormone releasing hormone and GH. Patients: The investigation was performed in 28 patients with non small cell lung carcinoma, in 44 patients with small cell lung carcinoma, and 10 patients with non malignant lung disease. A group of 37 normal subjects served as control. Measurements: Growth hormone releasing hormone and GH were determined by radioimmunoassay. Results: Patients with small cell lung carcinoma showed higher plasma growth hormone releasing hormone levels (49 ± 9.4 ng/l) than control subjects (16.3 ± 2.1 ng/l; P <0.05), patients with non small cell lung carcinoma (23.9 ± 8.8 ng/l; P <0.05), and patients with non malignant lung disease (12.7 ± 5.5; P <0.05). Basal GH level was lower in 5 μg/l in all patients except five patients with small cell lung carcinoma and one patient with non small cell lung carcinoma. Conclusions: The higher plasma growth hormone releasing hormone levels in patients with small cell lung carcinoma compared to normal controls and patients with non small cell lung carcinoma and patients with non malignant lung disease, confirm the frequent neuroendocrine activity of this particular tumour.

Original languageEnglish
Pages (from-to)463-467
Number of pages5
JournalClinical Endocrinology
Volume34
Issue number6
Publication statusPublished - 1991

Fingerprint

Growth Hormone-Releasing Hormone
Carcinoma
Lung
Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
Growth Hormone
Lung Diseases
Radioimmunoassay

ASJC Scopus subject areas

  • Endocrinology

Cite this

Schopohl, J., Losa, M., Frey, C., Wolfram, G., Huber, R., Permanetter, W., ... Von Werder, K. (1991). Plasma growth hormone (GH)-releasing hormone levels in patients with lung carcinoma. Clinical Endocrinology, 34(6), 463-467.

Plasma growth hormone (GH)-releasing hormone levels in patients with lung carcinoma. / Schopohl, J.; Losa, M.; Frey, C.; Wolfram, G.; Huber, R.; Permanetter, W.; Von Pawel, J.; Muller, O. A.; Von Werder, K.

In: Clinical Endocrinology, Vol. 34, No. 6, 1991, p. 463-467.

Research output: Contribution to journalArticle

Schopohl, J, Losa, M, Frey, C, Wolfram, G, Huber, R, Permanetter, W, Von Pawel, J, Muller, OA & Von Werder, K 1991, 'Plasma growth hormone (GH)-releasing hormone levels in patients with lung carcinoma', Clinical Endocrinology, vol. 34, no. 6, pp. 463-467.
Schopohl J, Losa M, Frey C, Wolfram G, Huber R, Permanetter W et al. Plasma growth hormone (GH)-releasing hormone levels in patients with lung carcinoma. Clinical Endocrinology. 1991;34(6):463-467.
Schopohl, J. ; Losa, M. ; Frey, C. ; Wolfram, G. ; Huber, R. ; Permanetter, W. ; Von Pawel, J. ; Muller, O. A. ; Von Werder, K. / Plasma growth hormone (GH)-releasing hormone levels in patients with lung carcinoma. In: Clinical Endocrinology. 1991 ; Vol. 34, No. 6. pp. 463-467.
@article{530038c513f648ad9543638d613098e7,
title = "Plasma growth hormone (GH)-releasing hormone levels in patients with lung carcinoma",
abstract = "Objective: The aim was to investigate the serum levels of growth hormone releasing hormone and GH in patients with lung carcinoma. Design: After an overnight fast a plasma sample was collected for determination of growth hormone releasing hormone and GH. Patients: The investigation was performed in 28 patients with non small cell lung carcinoma, in 44 patients with small cell lung carcinoma, and 10 patients with non malignant lung disease. A group of 37 normal subjects served as control. Measurements: Growth hormone releasing hormone and GH were determined by radioimmunoassay. Results: Patients with small cell lung carcinoma showed higher plasma growth hormone releasing hormone levels (49 ± 9.4 ng/l) than control subjects (16.3 ± 2.1 ng/l; P <0.05), patients with non small cell lung carcinoma (23.9 ± 8.8 ng/l; P <0.05), and patients with non malignant lung disease (12.7 ± 5.5; P <0.05). Basal GH level was lower in 5 μg/l in all patients except five patients with small cell lung carcinoma and one patient with non small cell lung carcinoma. Conclusions: The higher plasma growth hormone releasing hormone levels in patients with small cell lung carcinoma compared to normal controls and patients with non small cell lung carcinoma and patients with non malignant lung disease, confirm the frequent neuroendocrine activity of this particular tumour.",
author = "J. Schopohl and M. Losa and C. Frey and G. Wolfram and R. Huber and W. Permanetter and {Von Pawel}, J. and Muller, {O. A.} and {Von Werder}, K.",
year = "1991",
language = "English",
volume = "34",
pages = "463--467",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Plasma growth hormone (GH)-releasing hormone levels in patients with lung carcinoma

AU - Schopohl, J.

AU - Losa, M.

AU - Frey, C.

AU - Wolfram, G.

AU - Huber, R.

AU - Permanetter, W.

AU - Von Pawel, J.

AU - Muller, O. A.

AU - Von Werder, K.

PY - 1991

Y1 - 1991

N2 - Objective: The aim was to investigate the serum levels of growth hormone releasing hormone and GH in patients with lung carcinoma. Design: After an overnight fast a plasma sample was collected for determination of growth hormone releasing hormone and GH. Patients: The investigation was performed in 28 patients with non small cell lung carcinoma, in 44 patients with small cell lung carcinoma, and 10 patients with non malignant lung disease. A group of 37 normal subjects served as control. Measurements: Growth hormone releasing hormone and GH were determined by radioimmunoassay. Results: Patients with small cell lung carcinoma showed higher plasma growth hormone releasing hormone levels (49 ± 9.4 ng/l) than control subjects (16.3 ± 2.1 ng/l; P <0.05), patients with non small cell lung carcinoma (23.9 ± 8.8 ng/l; P <0.05), and patients with non malignant lung disease (12.7 ± 5.5; P <0.05). Basal GH level was lower in 5 μg/l in all patients except five patients with small cell lung carcinoma and one patient with non small cell lung carcinoma. Conclusions: The higher plasma growth hormone releasing hormone levels in patients with small cell lung carcinoma compared to normal controls and patients with non small cell lung carcinoma and patients with non malignant lung disease, confirm the frequent neuroendocrine activity of this particular tumour.

AB - Objective: The aim was to investigate the serum levels of growth hormone releasing hormone and GH in patients with lung carcinoma. Design: After an overnight fast a plasma sample was collected for determination of growth hormone releasing hormone and GH. Patients: The investigation was performed in 28 patients with non small cell lung carcinoma, in 44 patients with small cell lung carcinoma, and 10 patients with non malignant lung disease. A group of 37 normal subjects served as control. Measurements: Growth hormone releasing hormone and GH were determined by radioimmunoassay. Results: Patients with small cell lung carcinoma showed higher plasma growth hormone releasing hormone levels (49 ± 9.4 ng/l) than control subjects (16.3 ± 2.1 ng/l; P <0.05), patients with non small cell lung carcinoma (23.9 ± 8.8 ng/l; P <0.05), and patients with non malignant lung disease (12.7 ± 5.5; P <0.05). Basal GH level was lower in 5 μg/l in all patients except five patients with small cell lung carcinoma and one patient with non small cell lung carcinoma. Conclusions: The higher plasma growth hormone releasing hormone levels in patients with small cell lung carcinoma compared to normal controls and patients with non small cell lung carcinoma and patients with non malignant lung disease, confirm the frequent neuroendocrine activity of this particular tumour.

UR - http://www.scopus.com/inward/record.url?scp=0025822261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025822261&partnerID=8YFLogxK

M3 - Article

VL - 34

SP - 463

EP - 467

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 6

ER -